Education
About Us
Working with TipRanks
Follow Us
Metagenomi, Inc. (MGX)
NASDAQ:MGX
MGX Stock Chart & Stats
$1.75
-$0.33(-10.00%)
At close: 4:00 PM EST
$1.75
-$0.33(-10.00%)
Day’s Range― - ―
52-Week Range$1.23 - $4.00
Previous CloseN/A
Volume382.73K
Average Volume (3M)883.52K
Market Cap
$67.21M
Enterprise Value-$107.01M
Total Cash (Recent Filing)$184.11M
Total Debt (Recent Filing)$41.66M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Apr 01, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding37,546,436
10 Day Avg. Volume1,405,864
30 Day Avg. Volume883,524
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.58
Price to Sales (P/S)2.58
P/FCF Ratio-1.20
Enterprise Value/Market Cap-1.59
Enterprise Value/Revenue-3.46
Enterprise Value/Gross Profit-15.11
Enterprise Value/Ebitda1.27
Forecast
1Y Price Target
$8.67Price Target Upside395.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Preclinical Efficacy And SafetyNon-human primate dose-finding studies demonstrated durable Factor VIII expression with a favorable safety profile, supporting the program's therapeutic potential.
Regulatory MilestoneIND/CTA filing for the Hemophilia A program is on track for 2026 and could catalyze clinical validation and renewed partner interest if accepted.
Valuation UpsideThe stock trades significantly below company cash, creating upside potential for investors if development milestones are met.
Bears Say
Clinical Development RiskOngoing programs face the possibility of delays or unfavorable clinical data, which could materially impact company valuation and investor sentiment.
Portfolio ConcentrationPipeline re-prioritization narrows the development portfolio, increasing vulnerability to setbacks in the prioritized assets.
Workforce And Execution RiskA 25% workforce reduction raises execution risk and may slow progress as resources are concentrated on fewer programs.
Metagenomi, Inc. News
MGX FAQ
What was Metagenomi, Inc.’s price range in the past 12 months?
Metagenomi, Inc. lowest stock price was $1.23 and its highest was $4.00 in the past 12 months.
What is Metagenomi, Inc.’s market cap?
Metagenomi, Inc.’s market cap is $67.21M.
When is Metagenomi, Inc.’s upcoming earnings report date?
Metagenomi, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 77 days.
How were Metagenomi, Inc.’s earnings last quarter?
Metagenomi, Inc. released its earnings results on Nov 11, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.584 by $0.034.
Is Metagenomi, Inc. overvalued?
According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued.
Does Metagenomi, Inc. pay dividends?
Metagenomi, Inc. does not currently pay dividends.
What is Metagenomi, Inc.’s EPS estimate?
Metagenomi, Inc.’s EPS estimate is -0.61.
How many shares outstanding does Metagenomi, Inc. have?
Metagenomi, Inc. has 37,546,436 shares outstanding.
What happened to Metagenomi, Inc.’s price movement after its last earnings report?
Metagenomi, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.584. Following the earnings report the stock price went down -15.455%.
Which hedge fund is a major shareholder of Metagenomi, Inc.?
Currently, no hedge funds are holding shares in MGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Metagenomi, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Price Target Potential
395.24% Upside
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (395.43% Upside)
$8.67 (395.43% Upside)
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.26%
12-Months-Change
Fundamentals
Return on Equity
-40.87%
Trailing 12-Months
Asset Growth
-29.44%
Trailing 12-Months
Company Description
Metagenomi, Inc.
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
MGX Stock 12 Month Forecast
Average Price Target
$8.67
▲(395.43% Upside)
Technical Analysis
Oramed Pharm
―
Immunic
―
Atara Biotherapeutics
―
Werewolf Therapeutics
―
Context Therapeutics
―
Ownership Overview
9.29% Insiders
4.00% Mutual Funds
6.59% Other Institutional Investors
77.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---